Quality of Life and Economic Repercussions of Combining Proactive Medication Assessment and Electronic Monitoring of Toxicities in Subjects Undergoing Oral Cancer Therapy

Inclusion Criteria: * Patient starting oral therapy treatment in oncology for metastatic or locally advanced cancer * Patient able to use a connected electronic object * Patient with a smartphone/tablet or computer with internet access and an email address. * Patient with WHO status ≤2 * Patients receiving other cancer therapy concurrently with oral therapy may be included * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: * The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Patient pregnant, parturient or breast feeding * Illiterate patient * Patients with poor prognosis due to a serious uncontrolled medical condition, mild systemic disease, uncontrolled infection (cardiac, pulmonary, renal, etc.) * Patient receiving hormone therapy alone for breast or prostate cancer